전립선비대증 환자에서 Dutasteride 치료 후 혈 중 Prostate-specific antigen 치의 변화
The Effect of Dutasteride on Serum Prostate-specific Antigen (PSA) in Patients with BenignProstate Hypertrophy
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Purpose: 5α reductase, dutasteride, has widely used to treat enlarged prostate (BPH). By suppressing the conversion of testosterone to dihydrotestosterone it decreases serum prostate-specific antigen (PSA) which is very important screening marker for prostate cancer. We evaluate the early serum PSA changes after dutasteride treatment to Korean BPH patients. Materials and Methods: A total 159 men with a clinical diagnosis of BPH and no evidence of prostate cancer were enrolled. They were treated with dutasteride 0.5mg daily for 12 months. Serum PSA was evaluated at 2, 6, and 12 months after the medication. Result: Dutasteride statistically significantly reduced serum PSA to 0.70±0.52, 0.64±0.35, and 0.59±0.49 from baseline level at 2, 6, and 12 months after the medication, respectively. However, there was no statistical significance among the three groups in serum PSA changes after dutasteride. There were statistically significant correlations between a high pre-treatment serum PSA level and a large reduction of follow-up PSA levels at 2, 6, and 12 months after dutasteride treatment. Conclusions: The reduction of serum PSA is variable in patients to patients at 2, 6, and 12 months after dutasteride treatment. The patient with high initial serum PSA revealed a large reduction of serum PSA level after treatment. The traditional concept that follow-up serum PSA level should be doubled for prostate cancer screening may overestimate real serum PSA level within 12 months in Korean men receiving 5α reductase inhibitors. (J Korean Continence Soc 2008;12:42-47)
참고문헌 (21)
- Carson C 3rd, "Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia", Urology, 61(4), pp.2~7 (2003)
- Marberger M., "Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia", Nat Clin Pract Urol, 3, pp.495~503 (2006)
- Makridakis NM., "Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II", Pharmacogenetics, 10, pp.407~13 (2000)
- Cramer SD., "Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels", J Natl Cancer Inst, 95, pp.1044~53 (2003)
- Lee SE., "Ethnic differences in the age-related distribution of serum prostate-specific antigen values: a study in a healthy Korean male population", Urology, 56, pp.1007~1010 (2000)
- He D., "Ethnic differences in distribution of serum prostate-specific antigen: a study in a healthy Chinese male population", Urology, 63, pp.722~-6 (2004)
- Oesterling JE., "Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men", Br J Urol, 75, pp.347~353 (1995)
- Marks LS., "The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors:a review and clinical recommendations", J Urol, 176, pp.868~74 (2006)
- Andriole G., "The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge", J Urol, 174, pp.2098~104 (2005)
- 소병현, "전립선비대증 환자에서α-차단제 및 Finasteride 병용치료에 따른 PSA의 변화 양상: 3년간 추적관찰 결과", 대한비뇨기과학회지, 47(4), pp.372~376 (2006), 대한비뇨기과학회
- Keetch DW., "Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies", J Urol, 156, pp.428~31 (1996)
- 김정엽, "전립선암을 동반하지 않은 50세 이상의 남자에서 전립선특이항원치의 생물학적 변이", 대한비뇨기과학회지, 47(12), pp.1284~1288 (2006), 대한비뇨기과학회
- Qiu SD., "In situ hybridization of prostate-specific antigen mRNA in human prostate", J Urol, 144, pp.1550~6 (1990)
- Guess HA, "Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data", J Urol, 155, pp.3~9 (1996)
- Morgentaler A., "Re: The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors:a review and clinical recommendations", J Urol, 177, pp.1954~ (2007)
- Andriole G, "The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge", J Urol, 174, pp.2098~104 (2005)
- Brawer MK., "Effect of finasteride and", or terazosin on serum PSA: results of VA Cooperative Study #359, 1999, 234~9
- Roehrborn CG., "Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial", Urology, 50, pp.556~61 (1997)
- Başar MM., "The efficacy of alfuzosin treatment in patients with prostatism", Int Urol Nephrol, 33, pp.493~7 (2001)
- Debruyne F., "Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study", Eur Urol, 41, pp.497~-506 (2002)
- Mochtar CA., "PSA velocity in conservatively managed BPH: can it predict the need for BPH-related invasive therapy?", Prostate, 66, pp.1407~12 (2006)